NCT03147287 2025-09-30Palbociclib After CDK and Endocrine Therapy (PACE)Dana-Farber Cancer InstitutePhase 2 Active not recruiting220 enrolled 11 charts
NCT03414658 2025-07-02The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast CancerDana-Farber Cancer InstitutePhase 2 Active not recruiting100 enrolled 15 charts
NCT04215146 2025-01-16A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 StudyOncolytics BiotechPhase 2 Active not recruiting48 enrolled 13 charts
NCT03387085 2024-08-09QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.ImmunityBio, Inc.Phase 1/2 Terminated9 enrolled 18 charts
NCT03330405 2023-10-13Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid TumorsPfizerPhase 1/2 Terminated223 enrolled 50 charts
NCT02222922 2020-12-17A Study Of PF-06647020 For Adult Patients With Advanced Solid TumorsPfizerPhase 1 Completed138 enrolled 98 charts